Patents by Inventor Isabelle Sermadiras

Isabelle Sermadiras has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • HETERODIMERIC RELAXIN FUSIONS AND USES THEREOF
    Publication number: 20240025958
    Abstract: The present invention relates to heterodimeric Relaxin fusion polypeptides, in particular to heterodimeric Relaxin 2 fusion polypeptides and uses thereof. Thus, the invention provides Relaxin fusion polypeptides, nucleic acid molecules, vectors, host cells, pharmaceutical compositions and kits comprising the same and uses of the same including methods of treatment. The polypeptides and compositions of the invention may be useful, in particular, in the treatment of cardiovascular diseases, for example for the treatment of heart failure.
    Type: Application
    Filed: July 1, 2023
    Publication date: January 25, 2024
    Inventors: Isabelle SERMADIRAS, Monika Anna PAPWORTH, Judy Christiane PATERSON, Esther Marie MARTIN, Peng KE
  • Relaxin fusion polypeptides and uses thereof
    Patent number: 11845782
    Abstract: The present invention relates to Relaxin fusion polypeptides, in particular to Relaxin 2 fusion polypeptides and uses thereof. Thus, the invention provides Relaxin fusion polypeptides, nucleic acid molecules, vectors, host cells, pharmaceutical compositions and kits comprising the same and uses of the same including methods of treatment. The polypeptides and compositions of the invention may be useful, in particular, in the treatment of cardiovascular diseases, for example for the treatment of heart failure.
    Type: Grant
    Filed: November 17, 2021
    Date of Patent: December 19, 2023
    Assignee: MEDIMMUNE LIMITED
    Inventors: Weidong Hao, Andrew Garcia, Changshou Gao, Isabelle Sermadiras
  • Heterodimeric Relaxin fusions polypeptides
    Patent number: 11795205
    Abstract: The present invention relates to heterodimeric Relaxin fusion polypeptides, in particular to heterodimeric Relaxin 2 fusion polypeptides and uses thereof. Thus, the invention provides Relaxin fusion polypeptides, nucleic acid molecules, vectors, host cells, pharmaceutical compositions and kits comprising the same and uses of the same including methods of treatment. The polypeptides and compositions of the invention may be useful, in particular, in the treatment of cardiovascular diseases, for example for the treatment of heart failure.
    Type: Grant
    Filed: June 16, 2021
    Date of Patent: October 24, 2023
    Assignee: MEDIMMUNE LIMITED
    Inventors: Isabelle Sermadiras, Monika Anna Papworth, Judy Christiane Paterson, Esther Marie Martin, Peng Ke
  • RELAXIN FUSION POLYPEPTIDES AND USES THEREOF
    Publication number: 20220073584
    Abstract: The present invention relates to Relaxin fusion polypeptides, in particular to Relaxin 2 fusion polypeptides and uses thereof. Thus, the invention provides Relaxin fusion polypeptides, nucleic acid molecules, vectors, host cells, pharmaceutical compositions and kits comprising the same and uses of the same including methods of treatment. The polypeptides and compositions of the invention may be useful, in particular, in the treatment of cardiovascular diseases, for example for the treatment of heart failure.
    Type: Application
    Filed: November 17, 2021
    Publication date: March 10, 2022
    Inventors: Weidong HAO, Andrew GARCIA, Changshou GAO, Isabelle SERMADIRAS
  • Heterodimeric Relaxin Fusions and Uses Thereof
    Publication number: 20220017591
    Abstract: The present invention relates to heterodimeric Relaxin fusion polypeptides, in particular to heterodimeric Relaxin 2 fusion polypeptides and uses thereof. Thus, the invention provides Relaxin fusion polypeptides, nucleic acid molecules, vectors, host cells, pharmaceutical compositions and kits comprising the same and uses of the same including methods of treatment. The polypeptides and compositions of the invention may be useful, in particular, in the treatment of cardiovascular diseases, for example for the treatment of heart failure.
    Type: Application
    Filed: June 16, 2021
    Publication date: January 20, 2022
    Inventors: ISABELLE SERMADIRAS, MONIKA ANNA PAPWORTH, JUDY CHRISTIANE PATERSON, ESTHER MARIE MARTIN, PENG KE
  • Relaxin fusion polypeptides and uses thereof
    Patent number: 11192931
    Abstract: The present invention relates to Relaxin fusion polypeptides, in particular to Relaxin 2 fusion polypeptides and uses thereof. Thus, the invention provides Relaxin fusion polypeptides, nucleic acid molecules, vectors, host cells, pharmaceutical compositions and kits comprising the same and uses of the same including methods of treatment. The polypeptides and compositions of the invention may be useful, in particular, in the treatment of cardiovascular diseases, for example for the treatment of heart failure.
    Type: Grant
    Filed: January 24, 2018
    Date of Patent: December 7, 2021
    Assignees: Medlmmune, LLC, Medlmmune Limited
    Inventors: Weidong Hao, Andrew Garcia, Changshou Gao, Isabelle Sermadiras
  • RELAXIN FUSION POLYPEPTIDES AND USES THEREOF
    Publication number: 20190352366
    Abstract: The present invention relates to Relaxin fusion polypeptides, in particular to Relaxin 2 fusion polypeptides and uses thereof. Thus, the invention provides Relaxin fusion polypeptides, nucleic acid molecules, vectors, host cells, pharmaceutical compositions and kits comprising the same and uses of the same including methods of treatment. The polypeptides and compositions of the invention may be useful, in particular, in the treatment of cardiovascular diseases, for example for the treatment of heart failure.
    Type: Application
    Filed: January 24, 2018
    Publication date: November 21, 2019
    Inventors: Weidong HAO, Andrew GARCIA, Changshou GAO, Isabelle SERMADIRAS
  • GIP AND GLP-1 RECEPTOR DUAL-AGONISTS FOR THE TREATMENT OF DIABETES
    Publication number: 20160185837
    Abstract: This disclosure provides GIP/GLP-1 dual agonist polypeptides for the treatment of hypoglycemic conditions, e.g., type-2 diabetes.
    Type: Application
    Filed: August 15, 2014
    Publication date: June 30, 2016
    Applicant: Medimmune Limited
    Inventors: Maria Bednarek, Andie Collinson, David Hornigold, Siobhan O'Brien, Monika Papworth, Peter Ravn, Isabelle Sermadiras